Cargando…
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here, we investigated the immunostimulatory properties of F...
Autores principales: | Waldhauer, Inja, Gonzalez-Nicolini, Valeria, Freimoser-Grundschober, Anne, Nayak, Tapan K, Fahrni, Linda, Hosse, Ralf J., Gerrits, Danny, Geven, Edwin J. W., Sam, Johannes, Lang, Sabine, Bommer, Esther, Steinhart, Virginie, Husar, Elisabeth, Colombetti, Sara, Van Puijenbroek, Erwin, Neubauer, Markus, Cline, J. Mark, Garg, Pradeep K., Dugan, Gregory, Cavallo, Federica, Acuna, Gonzalo, Charo, Jehad, Teichgräber, Volker, Evers, Stefan, Boerman, Otto C., Bacac, Marina, Moessner, Ekkehard, Umaña, Pablo, Klein, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115765/ https://www.ncbi.nlm.nih.gov/pubmed/33974508 http://dx.doi.org/10.1080/19420862.2021.1913791 |
Ejemplares similares
-
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017) -
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
por: Bell, Charles J.M., et al.
Publicado: (2015) -
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
por: Peterson, Laurence B., et al.
Publicado: (2018) -
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells
por: Codarri Deak, Laura, et al.
Publicado: (2022) -
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
por: Herter, Sylvia, et al.
Publicado: (2016)